Specific killing of BRCA2-deficient tumours with inhibitors of poly(ADP-ribose) polymerase (original) (raw)

and we want to declare our relationship with these patents. N.J.C. and T.H., and T.H. alone, are named inventors on these patents, respectively, but are not owners of the patents nor do they have shares in the companies or institutions to which the patents belong. However, because the value of these patents has increased, owing to further results obtained in other laboratories since publication, N.J.C. and T.H. now wish to declare possible competing financial interests.

Sign up for access to the world's latest research.

checkGet notified about relevant papers

checkSave papers to use in your research

checkJoin the discussion with peers

checkTrack your impact